AVR's Principal Activity is the continued research and development of regenerative medicine.
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
1 Week | |
1 Month | |
2022 YTD | |
1 Year | |
vs Sector (1yr) | +78.62% |
vs ASX 200 (1yr) | +74.52% |
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is into continued research and development of regenerative medicine. Products under development in the aortic valve repair and replacement program include DurAVR. Combined with the ADAPT technology this design delivers better haemodynamic performance through unique properties that are critical to longer lasting valves.
Incorporated bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011
Head Office | Toowong QLD 4066 |
Website | www.anteristech.com |
Registry | Computershare |
Auditor | HLB Mann Judd Chartered Accountants |
Date Listed | 24 Mar 2004 |
Date | Event |
---|---|
19/05/2022 | AGM |
25/08/2022 | Report (Interim) |
24/02/2023 | Report (Prelim) |
25/04/2023 | Report (Annual) |
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
AVR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
The current holdings of AVR directors.
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
Perceptive Life Sciences Master Fund Ltd | 02/03/2022 | 1,840,000 | 14.00 |
L1 Capital Pty Ltd | 07/03/2022 | 1,137,029 | 8.39 |
Sio Partners LP | 18/12/2021 | 1,274,966 | 12.61 |
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
02-03-22 | Perceptive Life Sciences Master Fund Ltd | 1,840,000 | -- | 14.00 |
22-02-22 | L1 Capital Pty Ltd | 538,391 | 7.16 | 9.93 |
05-02-22 | Medicus Sciences Acquisition Corp | 1,274,966 | -- | 11.40 |
18-12-21 | Sio Partners LP | 12,286 | 14.38 | 12.61 |
01-11-21 | L1 Capital Pty Ltd | 625,000 | -- | 7.16 |
31-05-21 | Mercer Street Global Opportunity Fund LLC | 383,367 | -- | 5.52 |
12 month transaction history compiled from ASX announcements.
Date | Name | Sold | Previous % | New % |
---|---|---|---|---|
07-03-22 | L1 Capital Pty Ltd | 26,362 | 9.93 | 8.39 |
15-02-22 | Medicus Sciences Acquisition Corp | 1,274,966 | 11.40 | -- |
22-11-21 | Sio Partners LP | 48,399 | 19.96 | 14.38 |
19-07-21 | Mercer Street Global Opportunity Fund LLC | 383,367 | 5.52 | -- |
20-05-21 | Mercer Street Global Opportunity Fund LLC | 335,383 | 5.06 | -- |
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Year | Closing Price | Last Trade |
---|---|---|
2021 | $6.80 | 30 June |
2020 | $4.90 | 30 June |
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.